Can you take Glycerol phenylbutyrate with Tavist ND?

Glycerol phenylbutyrate has a moderate potential interaction with Liver Disease.

Patients with hepatic impairment may have higher plasma phenylacetate (PAA) and phenylacetate to phenylacetylglutamine (PAGN) ratio due to a reduced conversion capability of PAA to PAGN in the liver. Patients with moderate to severe hepatic impairment may require lower dosages of glycerol phenylbutyrate than normal to control the patient's ammonia levels. Caution is recommended in patients with hepatic impairment as no studies have been conducted.

The loratadine in Tavist ND has a moderate potential interaction with Liver Disease.

Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation. The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min). Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.

Glycerol phenylbutyrate has a moderate potential interaction with Malabsorption Syndrome.

Pancreatic enzymes hydrolyze glycerol phenylbutyrate in the small intestine. Intestinal disease resulting in fat malabsorption may result in reduced digestion of glycerol phenylbutyrate. It is recommended to monitor the ammonia levels closely in patients with pancreatic insufficiency or intestinal malabsorption.

Glycerol phenylbutyrate has a moderate potential interaction with Peripheral Neuropathy.

The major metabolite of glycerol phenylbutyrate, PAA, is associated with neurotoxicity. Cases of exacerbation of preexisting neuropathy have been documented in patients using this agent. It is recommended to exercise caution when using glycerol phenylbutyrate in patients with neuropathy.

Glycerol phenylbutyrate has a moderate potential interaction with Renal Dysfunction.

The efficacy and safety of glycerol phenylbutyrate in patients with renal impairment are unknown. It is recommended to monitor ammonia levels closely when using this agent in patients with impaired renal function.

The loratadine in Tavist ND has a moderate potential interaction with Renal Dysfunction.

Loratadine is primarily converted by the liver to an active metabolite, and both parent drug and metabolite are excreted in the urine. Patients with renal and/or liver disease may be at greater risk for adverse effects from loratadine due to drug and metabolite accumulation. The manufacturer recommends one-half the regular dosage initially in patients with liver failure or decreased renal function (GFR < 30 mL/min). Due to the differential effects of hepatic impairment on the serum half-life and clearance of loratadine and pseudoephedrine, the use of products containing a fixed combination of these drugs is not recommended in the presence of liver failure.